

## **New rotavirus vaccines from Asia: Rotavac, Rotasiil, Rotavin, RV3BB**

Rotavirus disease remains a major global cause of mortality and morbidity in children under 5 years of age. Rotavirus vaccines, RotaTeq and Rotarix, have been introduced into over 90 countries globally and have demonstrated substantial impact in reducing diarrheal mortality and diarrheal hospitalizations in young children. The vaccines are cost effective interventions for young children, particularly in countries with high diarrheal disease burden.

Significant advances have been made demonstrating the impact of the vaccines in low- and lower-middle income countries, yet, the full potential impact of rotavirus immunization is yet to be realized. Countries with large birth cohorts and where disease burden is high in Africa and Asia have not yet implemented rotavirus vaccines at all or at scale. In addition, despite the enormous strides forward, the effectiveness and impact is reduced in developing country settings, where the burden and mortality is highest.

New rotavirus vaccines, including live oral rotavirus candidates and non-replicating approaches continue to be developed, with the aim to improve the global supply and cost of rotavirus vaccines, and improve vaccine effectiveness in developing settings. This presentation will provide an overview of the new oral rotavirus vaccines from Asia, including Rotavac, RotaSiil, vaccines developed by Indian manufacturers as well as others that are under clinical development.